CSL Marks 40 Years in the Influenza Vaccine Market

CSL Limited today celebrated its 40th year as a

leading manufacturer of the influenza (flu) vaccine. The company´s

vaccine, Fluvax®, is

a Thiomersal-free influenza vaccine that is approved for use in adults

and children in Australia and New Zealand. This vaccine is known as

Afluriaâ„¢, Enziraâ„¢

Nilgripâ„¢, and X-Fluâ„¢ in 17 different countries, including the US and European markets.

Additionally, CSL supplies the antigen used to manufacture the flu

vaccine in 24 countries.
CSL´s prominence in the influenza vaccine market has grown dramatically

over the last 40 years. The company started its global flu vaccine

production in 1968, with the shipment of 1.2 million doses to Great

Britain -- CSL´s single-largest shipment of influenza vaccine at that

time. CSL now has an established history in influenza vaccine

development.
"At CSL Limited, we´re

proud of our track record of providing vaccine for what remains a

critical global healthcare need," said Mary

Sontrop, General Manager, CSL Biotherapies. "We´re

committed to consistently developing effective influenza vaccines based

on the strains recommended by health authorities, such as the World

Health Organization. As we prepare for the 2008-2009 influenza season

we look forward to providing consumers worldwide with an effective

quality product."
Recently completed, CSL Limited announced a $75 million (U.S.D.)

investment in plant and equipment to double the manufacturing capacity

of the company´s Melbourne facility to 40 million doses, making it one

of the largest vaccine manufacturing plants in the world. CSL has also

commenced construction of additional fill and finish capabilities in the

United States.
About Fluvax®
Fluvax® Influenza Virus Vaccine is indicated

for active immunization to prevent influenza disease caused by influenza

virus types A and B present in the vaccine in children and adults.
Fluvax® is available as a convenient single

use pre-filled syringe, containing a 0.5mL dose, which is

preservative-free and thiomersal-free.
Since 1985, more than 42 million doses of CSL´s influenza vaccine have

been distributed globally. This includes approximately 19.2 million

doses of CSL Biotherapies´ thiomersal-free formulation, distributed

since its first market introduction.
About CSL Limited
Headquartered in Melbourne, Australia, CSL Limited is a global

specialty biopharmaceutical company that develops, manufactures and

markets protein-based medicines to treat and prevent serious human

medical conditions. The CSL Group has a combined heritage of outstanding

contributions to medicine and human health with more than 90 years

experience in the development and manufacture of vaccines and plasma

protein biotherapies. Our strong commitment to funding research and

development of protein based biological medicines for unmet medical

needs underpins our continuing growth.
The CSL Group includes CSL Bioplasma, CSL Biotherapies and CSL Behring

incorporating ZLB Plasma. With major facilities in Australia, Germany

Switzerland and the U.S., CSL has over 8,600 employees operating in 27

countries.
About CSL Biotherapies
The U.S. headquarters of CSL Biotherapies are located in King of

Prussia, Pa. Its parent company, CSL Limited, in Melbourne, Australia

operates one of the world´s largest influenza vaccine facilities for

global markets. CSL Biotherapies, which shares its U.S. headquarters

with its sister company, CSL Behring, is commercializing influenza

vaccine products globally. At CSL Biotherapies, delivering vaccines is

our mission, protecting lives our passion. The CSL Group, which also

includes CSL Research & Development, CSL Bioplasma, and CSL Behring, has

more than 8,500 employees and operates in 21 countries worldwide. For

more information, visit us at www.cslbiotherapies-us.com, or call

1-888-435-8633.